PharmaCyte Biotech, Inc. (PMCB)
PMCB Stock Price Chart
Explore PharmaCyte Biotech, Inc. interactive price chart. Choose custom timeframes to analyze PMCB price movements and trends.
PMCB Company Profile
Discover essential business fundamentals and corporate details for PharmaCyte Biotech, Inc. (PMCB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
2 Jan 2013
Employees
2.00
Website
https://pharmacyte.comCEO
Joshua N. Silverman
Description
PharmaCyte Biotech, Inc. is a biotechnology firm dedicated to the development and commercialization of advanced cellular therapies within the United States. Their primary therapeutic areas include various forms of cancer, diabetes, and malignant ascites. Central to their efforts is Cell-in-a-Box, their proprietary encapsulation technology which utilizes cellulose to enclose live cells. This innovative platform serves as the foundation for treatments aimed at diverse cancers, such as advanced and inoperable pancreatic cancer, as well as diabetes. The company's pipeline includes therapies for pancreatic and other solid cancerous tumors; a treatment for Type 1 and insulin-dependent Type 2 diabetes involving encapsulated, genetically modified insulin-producing cells; and cancer treatments derived from cannabis plant compounds. To further its research, PharmaCyte maintains collaborative agreements: one with the University of Technology, Sydney, for the creation of melligen cells to combat diabetes, and another with the University of Northern Colorado, focusing on methods for identifying, separating, and quantifying cannabis constituents. Originally established in 1996, the company operated under the name Nuvilex, Inc. before rebranding as PharmaCyte Biotech, Inc. in January 2015. Its corporate headquarters are located in Las Vegas, Nevada.
PMCB Financial Timeline
Browse a chronological timeline of PharmaCyte Biotech, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 1 Jul 2026
Earnings released on 17 Mar 2026
EPS came in at $0.13 surpassing the estimated -$0.06 by +316.67%.
Earnings released on 18 Dec 2025
EPS came in at -$0.32 .
Earnings released on 15 Sept 2025
EPS came in at -$0.09 .
Earnings released on 11 Aug 2025
EPS came in at $1.73 .
Earnings released on 17 Mar 2025
EPS came in at -$0.10 .
Earnings released on 13 Dec 2024
EPS came in at -$0.29 .
Earnings released on 16 Sept 2024
EPS came in at $0.14 .
Earnings released on 13 Aug 2024
EPS came in at -$0.85 .
Earnings released on 18 Mar 2024
EPS came in at -$0.65 .
Earnings released on 15 Dec 2023
EPS came in at -$0.64 .
Earnings released on 18 Sept 2023
EPS came in at -$0.28 .
Earnings released on 31 Jul 2023
EPS came in at -$0.01 surpassing the estimated -$0.09 by +88.89%.
Earnings released on 16 Mar 2023
EPS came in at -$0.04 surpassing the estimated -$0.08 by +50.00%.
Earnings released on 14 Dec 2022
EPS came in at -$0.09 falling short of the estimated -$0.08 by -12.50%.
Earnings released on 14 Sept 2022
EPS came in at -$0.07 matching the estimated -$0.07.
Earnings released on 28 Jul 2022
EPS came in at -$0.06 falling short of the estimated -$0.03 by -74.98%.
Earnings released on 15 Mar 2022
EPS came in at -$0.04 surpassing the estimated -$0.05 by +20.00%.
Earnings released on 14 Dec 2021
EPS came in at -$0.06 surpassing the estimated -$0.07 by +14.29%.
Earnings released on 14 Sept 2021
EPS came in at -$0.64 .
Earnings released on 10 Aug 2021
EPS came in at -$0.62 .
PMCB Stock Performance
Access detailed PMCB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
